Drug interactions and bleeding complications with rivaroxaban compared to warfarin
- In: Poster presentation
- At: Seoul (South Korea) (2017)
- Type: Poster
- Poster code: POS-PPR-001
- By: CARDONA, Mark (Attard, Malta)
- Co-author(s): Mark George Cardona
Lilian M Azzopardi
BackgroundCompared to warfarin, the novel oral anticoagulant (NOAC) rivaroxaban has fewer potential drug-drug interactions (DDIs). However, there is conflicting evidence regarding bleeding complications.
PurposeTo compare rivaroxaban and warfarin with respect to potential DDIs and incidence and severity of bleeding.
Following ethics.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019